Skip to main content

Table 2 Crude seropositivity and testing for acute infection

From: High seroprevalence of SARS-CoV-2 in Burkina-Faso, Ghana and Madagascar in 2021: a population-based study

 

Bobo-Dioulasso

Ouagadougou

Fianarantsoa

Kumasi

 

n/N (%)

n/N (%)

n/N (%)

n/N (%)

Crude seropositivity

317 / 627 (50·6)f1

170 / 522 (32·6)f2

253 / 674 (37·5)f3

131 / 340 (38·8)f4

No test for acute infection performed since onset of pandemic

611 / 627 (97·4)

493 / 522 (94·4)

655 / 674 (97·2)

322 / 340 (94·7)

Test for acute infection performed prior to survey

16 / 627 (2·6)

29 / 522 (5·6)

19 / 674 (2·8)

18/340 (5·3)

Positive results for acute infection among those tested

2 / 16 (12·5)

1 / 29 (3·5)

4 / 19 (21·1)

2/18 (11·1)

  1. n N, sample size
  2. f1Of the remaining tested participants, 6 (1·0%) had an undefined and 304 (48·5%) a negative serological result
  3. f2Of the remaining tested participants, 6 (1·2%) had an undefined and 346 (66·3%) a negative serological result
  4. f3Of the remaining tested participants, 1 (0·2%) had an undefined and 420 (62·3%) a negative serological result
  5. f4Of the remaining tested participants, 13 (3·8%) had an undefined and 196 (57·7%) a negative serological result